AIM Vaccine Full Year 2024 Earnings: CN¥0.23 loss per share (vs CN¥1.07 loss in FY 2023)

Simply Wall St

AIM Vaccine (HKG:6660) Full Year 2024 Results

Key Financial Results

  • Revenue: CN¥1.29b (up 8.2% from FY 2023).
  • Net loss: CN¥277.2m (loss narrowed by 79% from FY 2023).
  • CN¥0.23 loss per share (improved from CN¥1.07 loss in FY 2023).
We've discovered 2 warning signs about AIM Vaccine. View them for free.

6660 Products In Clinical Trials

  • Phase I: 1.
  • Phase II: 1.
  • Phase III: 1.

6660 Post-Clinical Trial Products

  • Pre-registration: 2.
SEHK:6660 Revenue and Expenses Breakdown April 29th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

AIM Vaccine Earnings Insights

The primary driver behind last 12 months revenue was the Mainland China segment contributing a total revenue of CN¥1.28b (99% of total revenue). The largest operating expense was Sales & Marketing costs, amounting to CN¥542.7m (44% of total expenses). Explore how 6660's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in Hong Kong.

Performance of the Hong Kong Biotechs industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

We should say that we've discovered 2 warning signs for AIM Vaccine (1 doesn't sit too well with us!) that you should be aware of before investing here.

Valuation is complex, but we're here to simplify it.

Discover if AIM Vaccine might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.